Kalaris Therapeutics (KLRS) Current Leases (2019 - 2026)

Kalaris Therapeutics (KLRS) posted quarterly Current Leases of $317000.0 for Q1 2026, little changed quarter-over-quarter from $316000.0 in Q4 2025.

Kalaris Therapeutics (KLRS) Current Leases (2019 - 2026) Analysis & Trends

Kalaris Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $317000.0 for Q1 2026.

In Q1 2026, Current Leases changed N/A year-over-year to $317000.0; the TTM figure through Mar 2026 stood at $317000.0 (changed N/A YoY), while the FY2025 annual figure was $316000.0, changed N/A from the prior year.
Current Leases for Q1 2026 stood at $317000.0, roughly flat from $316000.0 in the prior quarter.
The five-year high for Current Leases was $13.0 million in Q3 2023, with the low at $316000.0 in Q4 2025.
The 5-year median for Current Leases is $2.3 million (2024), against an average of $4.5 million.
The sharpest annual moves came in 2023 and 2024: Current Leases jumped 576.54% in 2023, then plunged 92.14% in 2024.
Kalaris Therapeutics' Current Leases stood at $7.2 million in 2022, then soared by 50.47% to $10.8 million in 2023, then plunged by 93.81% to $667000.0 in 2024, then sank by 52.62% to $316000.0 in 2025, then climbed by 0.32% to $317000.0 in 2026.
Business Quant data shows KLRS's Current Leases at $317000.0 in Q1 2026, $316000.0 in Q4 2025, and $376000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Vertex Pharmaceuticals	140.39 Bn	132.54 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.47 Bn	78.47 Bn	3.93 Bn	720.00 Mn
3	Argenx Se	65.25 Bn	60.07 Bn	1.37 Bn	-
4	Moderna	61.79 Bn	56.66 Bn	52.00 Mn	-
5	BeOne Medicines	42.27 Bn	37.17 Bn	1.53 Bn	21.95 Mn
6	Alnylam Pharmaceuticals	31.17 Bn	27.86 Bn	992.69 Mn	45.93 Mn
7	BioNTech SE	28.61 Bn	10.22 Bn	668.28 Mn	-
8	Insmed	27.44 Bn	26.28 Bn	358.27 Mn	6.27 Mn
9	Royalty Pharma	27.30 Bn	26.46 Bn	-	-
10	Kalaris Therapeutics	97.57 Mn	97.57 Mn	-	347,000.00

Download Data